trending Market Intelligence /marketintelligence/en/news-insights/trending/J8ObrP5TOHNZ9i_5P23fMw2 content esgSubNav
In This List

Aclaris' Eskata wins FDA approval to treat non-cancerous skin growths

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Aclaris' Eskata wins FDA approval to treat non-cancerous skin growths

Aclaris Therapeutics Inc. said the U.S. Food and Drug Administration approved topical solution Eskata to treat non-cancerous skin growths.

Eskata is the first and only U.S. FDA approved topical, non-invasive treatment for the growths called raised seborrheic keratoses.

The company said the approval was based on two phase 3 trials that showed the safety and efficacy of Eskata. Patients treated with the medicine were more likely to have all four skin growths completely cleared after two treatments than patients who received placebo.

Eskata will be offered to patients as a self-pay aesthetic treatment and is expected to be commercially available in the spring of 2018.

Aclaris said it submitted a marketing authorization application for Eskata for treating seborrheic keratoses in select countries in the EU.